New Drug for Chronic Myeloid Leukemia Might Stimulate the Market

Cancer shared this article with you from Inoreader New Drug for Chronic Myeloid Leukemia Might Stimulate the Market Via Clinical Cancer Research recent ... The evolution of treatment options over the past 20 years has provided for a normal life expectancy for most patients with chronic myeloid leukemia. Currently approved tyrosine kinase inhibitors mainly differ in potency and side effect profile. Flumatinib goes for deep responses and good tolerability. See related article by Zhang et al., p. 70 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.